Articles Tagged With:
-
Rise of Private Equity Raises Ethical Conflicts in Emergency Medicine
In emergency medicine, there are growing ethical concerns that the role of private equity firms is putting profits above patient care.
-
Physician Selling Practice? Ethical Guidance Is Needed
As healthcare in America continues to consolidate, private independent practices or solo practitioners are fewer in number. A growing number of physicians are selling their practices to private equity firms or other buyers, raising ethical concerns.
-
Pediatric Ethics Consults Differ in the Outpatient vs. Inpatient Setting
When consulting on pediatric cases in the outpatient setting, ethicists see distinct issues compared to the inpatient setting, a recent study found.
-
Ethics Consult Requestors Validate Value of Ethicists, Voice Concerns About Access
What is the value of an ethics consultation? Clinical areas rely on hard data, such as an increase in the percentage of patients receiving medication in a specific timeframe, to demonstrate quality. For ethics, a “good” consult is much harder to define and is talked about in terms of qualitative, rather than quantitative, data.
-
How Does the 12-Lead Help?
You are given the electrocardiogram (ECG) in the figure without the benefit of any history. How would you interpret this tracing? How does the 12-lead ECG help with interpretation of the rhythm?
-
Xanomeline and Trospium Chloride Capsules (Cobenfy)
The U.S. Food and Drug Administration has approved the first-in-class muscarinic agonist and antagonists for the treatment of schizophrenia in adults. This is the first antipsychotic drug approved in decades and is unique in that it targets cholinergic receptors — unlike traditional agents, which target dopamine receptors.
-
A New Technique for Predicting Outcomes in Asymptomatic AS
An international study of patients with moderate or asymptomatic severe aortic stenosis has demonstrated that increased amounts of left ventricular fibrosis, as measured by cardiac magnetic resonance imaging, is associated with worse outcomes.
-
Antithrombotic Treatment for Atrial Fibrillation After Acute Coronary Events
An analysis of the AUGUSTUS trial comparing a P2Y12 inhibitor plus four combinations of double or triple therapy with apixaban, aspirin, and a vitamin K antagonist in patients with atrial fibrillation and a recent acute coronary event or percutaneous coronary intervention has shown that a P2Y12 inhibitor plus apixaban exhibited the lowest rate of major adverse events and major bleeding events.
-
Screening for Atrial Fibrillation in Older Adults
A two-week ambulatory electrocardiogram monitor in a large group of individuals 70 years of age or older with no history of atrial fibrillation (AF) showed a very low incidence of AF (4.4%), almost all of which was paroxysmal. In less than 2% of the subjects did it represent ≥ 2% of the monitoring time. However, some patients had hours of AF, raising a concern for thromboembolic risk.
-
A New Drug for Heart Failure with Preserved Ejection Fraction?
The addition of the nonsteroidal mineralocorticoid receptor antagonist finerenone to standard therapy reduced the incidence of recurrent heart failure and death compared to placebo in patients with heart failure and mildly reduced or preserved left ventricular ejection fraction and was generally well tolerated.